Spermosens AB (publ) to Host Live Q&A Town Hall on 19 November 2026

Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A town hall on Thursday, 19 November 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company's recent announcements.

The session is organized as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The town hall follows the publication of the Company's Q3 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the publication of each quarterly report.

Town Hall Details

- **Date:** Thursday, 19 November 2026
- **Time:** 12:00 CET
- **Language:** English and Swedish
- **Join Town Hall meeting:**

http://teams.microsoft.com/l/meetup-join/19%3ameeting_Zjk1ZDQ5OTEtOWNkNC00MTg2LWIyMzYtYmZkNTc4NWYyODVh%40thread.v2/0?context=%7b%22Tid%22%3a%227a6fe723-25f0-4904-8ffa-2bbf2e6af406%22%2c%22Oid%22%3a%2223998060-0cf4-4e02-9910-1e2cc4e0f55f%22%7d

Participation and Submission of Questions

The town hall is open to all interested parties. Participants are invited to submit questions in advance or during the session. The Company may consolidate similar questions to address as many topics as possible. Answers will be limited to information that has already been made public.

- **Advance Questions:** Please email info@spermosens.com
- **Questions During the Session:** Please use the Q&A function in Teams
- **Deadline for Advance Questions:** Wednesday, 18 November 2026

For more information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com

About Spermosens AB
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve

their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market.
The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com.